Relapse in Schizophrenia Clinical Trial
— SereNISOfficial title:
Seroquel XR in the Long Term Treatment of Schizophrenia Focus on Affective Symptoms
Verified date | October 2011 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | Hungary: National Institute of Pharmacy |
Study type | Observational |
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
Status | Completed |
Enrollment | 1606 |
Est. completion date | October 2011 |
Est. primary completion date | October 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month Exclusion Criteria: - Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Hungary | Research Site | Baja | |
Hungary | Research Site | Balassagyarmat | |
Hungary | Research Site | Barcs | |
Hungary | Research Site | Berettyoujfalu | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Cegled | |
Hungary | Research Site | Csongrad | |
Hungary | Research Site | Debrecen | |
Hungary | Research Site | Dombovar | |
Hungary | Research Site | Dunaujvaros | |
Hungary | Research Site | Eger | |
Hungary | Research Site | Emod | |
Hungary | Research Site | ERD | |
Hungary | Research Site | Esztergom | |
Hungary | Research Site | Godollo | |
Hungary | Research Site | Gyongyos | |
Hungary | Research Site | Gyor | |
Hungary | Research Site | Gyula | |
Hungary | Research Site | Hajdusamson-Martinka | |
Hungary | Research Site | Hajduszoboszlo | |
Hungary | Research Site | Heves | |
Hungary | Research Site | Janoshalma | |
Hungary | Research Site | Jaszbereny | |
Hungary | Research Site | Kalocsa | |
Hungary | Research Site | Karcag | |
Hungary | Research Site | Kecskemet | |
Hungary | Research Site | Kerepestarcsa | |
Hungary | Research Site | Ketegyhaza | |
Hungary | Research Site | Kiskunhalas | |
Hungary | Research Site | Kiskunmajsa | |
Hungary | Research Site | Kistokaj | |
Hungary | Research Site | Komarom | |
Hungary | Research Site | Kozarmisleny | |
Hungary | Research Site | Miskolc | |
Hungary | Research Site | Nagyatad | |
Hungary | Research Site | Nagykallo | |
Hungary | Research Site | Nagykanizsa | |
Hungary | Research Site | Nagykoros | |
Hungary | Research Site | Ny?regyhaza | |
Hungary | Research Site | Pecs | |
Hungary | Research Site | Pomaz | |
Hungary | Research Site | Salgotarjan | |
Hungary | Research Site | Satoraljaujhely | |
Hungary | Research Site | Soltvadkert | |
Hungary | Research Site | Sopron | |
Hungary | Research Site | Szeged | |
Hungary | Research Site | Szeghalom | |
Hungary | Research Site | Szekesfehervar | |
Hungary | Research Site | Szekszard | |
Hungary | Research Site | Szentendre | |
Hungary | Research Site | Szentes | |
Hungary | Research Site | Szigetszentmiklos | |
Hungary | Research Site | Szigetvar | |
Hungary | Research Site | Szolnok | |
Hungary | Research Site | Szombathely | |
Hungary | Research Site | Tata | |
Hungary | Research Site | Tatabanya | |
Hungary | Research Site | Toszeg | |
Hungary | Research Site | Vac | |
Hungary | Research Site | Veszprem | |
Hungary | Research Site | Zalegerszeg |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Hungary,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of patients remained relapse free after 6 months of treatment | on the 60th day of treatment | No | |
Primary | Rate of patients remained relapse free after 6 months of treatment | on the 180th day of treatment | No | |
Secondary | connection between relapse and affective symptoms | on the 60th day of treatment | No | |
Secondary | connection between relapse and affective symptoms | 180th day of treatment | No |